TP53 and cancer: Generated 25 years ago from the colorectal cancer cell line HCT116 [1] and widely distributed thereafter, the original human somatic cell p53-knockouts exhibit many cancer-relevant phenotypes, such as loss of cell cycle checkpoints and resistance to 5-fluorouracil (5-FU) [2], a first line therapeutic agent for CRC.